Abstract Amyloid-b (Ab) deposits are detectable in the brain in vivo using positron emission tomography (PET) and [C-11] 
Introduction
Alzheimer's disease (AD) is characterized neuropathologically by extracellular amyloid-beta (Ab)-containing plaques and intracellular neurofibrillary tangles (NFT) of aggregated tau protein [8, 20, 36] . Positron emission tomography (PET) using radiolabeled amyloid binding compounds, such as [C-11]-labeled Pittsburgh Compound B (PiB), detects Ab-containing amyloid deposits in vivo [23, 24, 31, 32] . Compared to cognitively normal controls, AD patients typically have two-to three-fold higher [C-11] PiB PET retention levels in brain areas known to accumulate high amounts of Ab plaques in AD, including the frontal, temporal, and occipital cortices [24, 38] . However, [C-11] PiB PET retention does not always reflect a clinical diagnosis of AD, as detectable [C-11] PiB PET retention levels are reported in approximately 25% of cognitively normal elderly [1, 35, 37, 43, 44] . These results corroborate previous autopsy reports of Ab plaques in cognitively intact people [3, 4, 9, 13, 39, 50] . For example, using CERAD criteria in 97 nondemented elderly cases from 7 Alzheimer's Disease Centers, Price and colleagues found that approximately 40% of cases had substantial Ab plaque pathology with 19% meeting a neuropathological diagnosis of possible AD, another 19% meeting criteria for probable AD, and 2% meeting criteria for definite AD [40] . The minimum level of amyloid pathology associated with detectable [C-11]PiB retention has not been established; insight into this issue would clarify the utility of PiB PET imaging as an in vivo diagnostic tool. Current research is, therefore, focused on examining the correlations between in vivo amyloid imaging and postmortem histological, immunohistochemical and biochemical analyses of amyloid markers in the same subject. To date there are eight published studies of 16 postmortem cases that were [C-11]PiB PET imaged antemortem (Table 1) , with equal numbers of cases having positive [2, 5, 16, 17, 19, 46] and negative antemortem PET scans [5, 6, 46, 49] . The current study extends these reports by comparing amyloid plaque load, Ab1-40 and Ab1- 42 
Methods
In all histological and biochemical experiments, tissue sections and homogenates from the [C-11]PiB(-) and [C-11]PiB(?) cases were processed simultaneously using the identical methodology.
Clinical case data
The [C-11]PiB(-) subject first presented to the University of Pittsburgh Alzheimer's Disease Research Center (ADRC) at age 70. He had a history of REM sleep-behavioral disturbances and suffered a transient ischemic attack at age 64. This was reflected on his first MR imaging, performed at age 69, which revealed an old ischemic lesion in the left cerebellar hemisphere; however, clinical examination revealed no permanent neurological deficits. Cognitive impairment began at age 67 with executive function problems and progressed to memory difficulties leading to suspicion of AD and, subsequently, therapy with Aricept (MMSE = 26 at age 70). Over the next two years cognitive decline progressed and was accompanied by visual hallucinations (MMSE = 25 at age 72). At this age, the patient was also given a rating of 9 on the New York University scale for parkinsonism [14] , indicating mild parkinsonism. At age 73, he was diagnosed with probable DLB and possible AD with cerebrovascular disease. At age 74, cognitive impairment continued to worsen (MMSE = 17) and CERAD extrapyramidal score was 23 [7] , indicating moderate parkinsonism. At his last ADRC visit (MMSE = 10 at age 78), 17 months [16] . The left cerebral hemisphere was placed in 10% buffered formalin, and after 21 days fixation sliced into 1-cm thick axial blocks as in [16] . CERAD designated brain regions were sampled for diagnostic purposes [36] . To quantify regional plaque load, sixteen 1 cm 3 tissue cubes (volumes of interest, VOIs) were dissected from an axial tissue block of the [C-11]PiB(-) brain, matching the same VOIs dissected previously from the [C-11]PiB(?) brain [16] . White matter was excluded from analyses due to nonspecific retention of [C-11]PiB [24] . Fixed tissue VOI cubes were cut in half along a plane parallel to their ventral face and each cube yielded two 1 cm 9 1 cm 9 0.5 cm tissue blocks. One half was immersed in 4% paraformaldehyde for 24 h, cryoprotected in sucrose, frozen, and sectioned into 40 lm thick tissue sections for free-floating immunohistochemistry. The other half was embedded in paraffin, and sectioned into sequential 6 lm-thick sections. Free-floating tissue sections served to quantify plaque load, while serial paraffin sections were used to examine the spatial relationship of plaques labeled with Ab antibodies and the fluorescent amyloid binding compounds 6-CN-PiB, thioflavin S, and X-34.
Histology and immunohistochemistry
Histofluorescence studies were performed on 6 lm paraffin sections and 40 lm slide-mounted frozen sections according to previously published procedures [16] . Both types of sections were processed using thioflavin S (0.5 g/L) and the highly-fluorescent Congo red derivative, X-34 (0.04 g/L). Similar results were obtained using the two compounds; however, X-34 consistently had better sensitivity for all forms of amyloid, in agreement with reports published previously [15, 16, 47] , and was, therefore, used in the current report. 6-CN-PiB (10 lM, a highly fluorescent derivative of PiB) histofluorescent labeling, which is limited to plaque and vascular deposits of Ab [16, 32] , and immunohistochemical procedures with an array of Ab antibodies (see Table 2 ) were performed using previously published protocols [16] . Histological and Ab immunohistochemical plaque loads were quantified using NIH Image (Rasband, W.S., ImageJ, US National Institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/, 1997-2009) in three sections equally spaced through each VOI. Sections from each brain region examined contained both white and gray matter. Images used for plaque load analysis were taken exclusively in the gray matter areas, avoiding the crest of gyri and the depths of sulci. Adjacent sections were processed using cresyl violet and used to determine the boundaries between white and gray matter. Low magnification, high resolution images of histofluorescence and immunohistochemistry in gray matter areas were acquired using a motorized stage and the Virtual Slice module of StereoInvestigator (Microbrightfield, Inc., Williston, VT, USA). All plaques were [18] Ab42 (rabbit) Ala-42 1:1,000 Chemicon (LV1378370) [18] N3pE (rabbit) Pyroglutamate 1:1,000 IBL (9I-916) [45] aa amino acids, b biotin-labeled antibody quantified regardless of their morphology. Bielschowsky silver staining was done according to the Yamamoto and Hirano modification [52] in frontal, occipital, superior temporal, and inferior parietal cortices as a routine neuropathological diagnostic procedure following CERAD guidelines [36] .
Classification of cerebral amyloid plaques
Senile plaques are parenchymal deposits of Ab amyloid fibrils and associated molecular components [10] . In this study, we describe plaques based on their morphology. Supplemental Fig. 1 illustrates the four main plaque types visualized using Ab immunohistochemistry and X-34 in this study. Diffuse plaques are defined as loosely organized deposits of Ab amyloid fibrils, primitive plaques as wellcircumscribed deposits with prominent labeling throughout the plaque but without a central core, classic plaques as deposits with a distinct halo around a dense core of amyloid, and burnt out plaques as dense cores of amyloid that lack classic plaques' distinct halo.
Biochemical assays
Fresh-frozen tissue samples free of visible white matter were homogenized and processed for [H-3]PiB binding assay as described [16] . Results were corrected for nonspecific, non-displaceable binding in the presence of 1 lM PiB and expressed as picomoles [H-3]PiB bound per gram (pmoles/g) of wet tissue weight. Aliquots of the same brain tissue homogenates were processed for enzyme linked immunosorbant assay (ELISA) analyses of Ab1-42 or Ab1-40 following a published protocol [16] . Total (diethylamine and formic acid-extracted) pools of Ab1-42 and Ab1-40 were assessed, and values expressed as pmoles/g wet brain tissue, determined from a standard curve using synthetic Ab1-42 or Ab1-40 peptides.
PET imaging and calculation of [C-11]PiB DVR values
The [C-11]PiB(-) case underwent [C-11]PiB PET and MR imaging 17 months prior to death. A spoiled gradient recalled MR scan (1.5 T, GE Signa) was obtained for anatomical region of interest (ROI) definition. The PET data were acquired as previously described [29, 38] 60 s, 2 9 180 s, 8 9 300 s), corrected for attenuation, scatter, and radioactive decay, and reconstructed using filtered back-projection. The reconstructed PET image resolution was approximately 6 mm full width at half maximum in the transverse and axial planes. Matching of the autopsy tissue cube sampling to the ROI sampling of the dynamic PET image data was based on a previously described method [16] . ROI-labeled images of axial autopsy slices guided ROI generation on the antemortem full-resolution axial MR. Each subject's MR image was reoriented to match the orientation of the autopsy slice image and ROIs were generated on the reoriented MR to match those on the autopsy image. The PET image was then co-registered to the reoriented MR image using automated methods [38] and regional [C-11]PiB time-activity curves were generated.
[C-11]PiB retention was assessed using the reference Logan graphical analysis [28] to generate the distribution volume ratio (DVR; 35-60 min after injection, using cerebellum as reference region). The regional DVR values were determined using the 35-60 min integration intervals and corrected for atrophy-related CSF dilution [29, 38] . The DVR is a unitless value related directly to the free bindingsite pool (Bmax) and the ligand dissociation constant (Kd) [34] and, in this work, provides a measure of specific [C-11]PiB retention.
Visual ratings
Images from the [C-11]PiB(-) and the [C-11]PiB(?) cases, additional positive and negative cases, and two borderline cases were given to three individuals experienced in reading [C-11]PiB PET scans. Each individual independently rated each case as either definitely positive, probably positive, probably negative, or definitely negative.
Statistical analyses
Correlation analyses were performed using basic linear regression. Comparisons of means were determined using Student's T test. Statistical significance was set at 0.05 (two-sided).
Results

[C-11]PiB PET imaging
Parametric [C-11]PiB DVR images (35-60 min using cerebellum as reference) were generated for visual comparison purposes using the reference Logan method (Fig. 1) . These DVR images exhibited very similar distributions of [C-11] PiB retention compared to images generated using either simple summed tissue ratios (i.e., SUVR) or the simplified reference tissue model (SRTM2) of Wu and Carson [51] (not shown). Three experienced, blinded readers independently visually rated the clinically diagnosed DLB case as definitely negative based on the lack of specific [C-11]PiB retention in any gray matter region ( Fig. 1, top row) . The clinically severe AD case was visually rated definitely positive (Fig. 1, bottom row) . The highest atrophy-corrected DVR values in the left hemisphere of the [C-11]PiB(-) case were 1.25 (occipital cortex), 1.12 (frontal), and 1.09 (temporal cortex). In the right hemisphere of the [C-11]PiB(-) case, the highest values of atrophy-corrected DVR values were recorded in the frontal pole, superior frontal cortex, and occipital cortex (all DVR = 1.10). DVR values from all gray and white matter regions were below the atrophy-corrected DVR of 1.4 which has been defined as a conservative cutoff for positive [C-11]PiB PET retention [1] . This is in contrast to the robust retention signal detected in both hemispheres from the [C-11]PiB(?) brain; in the left hemisphere, atrophy-corrected DVRs ranged from 1.71 in the occipital cortex to 2.6 in the frontal cortex, and striatal retention was 1.88, while in the right hemisphere DVR values ranged from 1.59 in the occipital cortex to 2.38 in the frontal cortex, and striatal retention was 1.92 ( Fig. 1, bottom row) .
Neuropathology
The fresh brain of the [C-11]PiB(-) DLB case weighed 1,370 g, with no signs of vascular anomalies or aneurysms, and no hemorrhages. There was mild cortical atrophy of the frontal and parietal lobes, minimal atrophy of the temporal lobes, and no notable atrophy of the hippocampus. Upon microscopic examination, hematoxylin and eosin staining showed no neuronal loss or gliosis in cortical areas. Immunohistochemistry with Ab antibodies (4G8 and 6E10, see Table 2 ) revealed moderate to focally frequent plaques in the frontal and occipital (primary visual) cortices, sparse to focally moderate plaques in temporal lobes and cingulate gyrus, and sparse plaques in the inferior parietal lobe. No plaques were detected in the cerebellum, thalamus, or caudate. CAA was focally moderate in the occipital lobe, and mild in other neocortical areas. There were only a few isolated foci of sparse CAA in the cerebellum. Bielschowsky positive neuritic plaques were generally sparse in frontal, parietal, temporal, and occipital lobes; only a single focus in the superior temporal cortex and several areas of the frontal cortex had moderate numbers of neuritic plaques. There was a single area of frequent neuritic plaques in the frontal cortex; the latter finding and strict application of the CERAD criteria [36] allow for the neuropathological diagnosis of definite AD. However, the overall impression of the neuropathologist (R.L.H.), from Ab immunohistochemistry and Bielschowsky silver staining, was that the AD pathology was mild. NFT were confined to the entorhinal cortex and hippocampus (Braak stage II). Based on the NIA-Reagan Institute criteria [8] , there was a low likelihood that the AD pathology was the cause of dementia in this case. Alphasynuclein-immunoreactive Lewy bodies were abundant in the cingulate gyrus and moderate in the frontal lobe, but mild in the parietal and temporal lobes. There was severe a-synuclein pathology in the nucleus basalis of Meynert, olfactory bulb, substantia nigra, and both the pontine and medullary tegmentum. Using the most recent criteria [11, 33] , this case was designated as DLB, neocortical type. Histochemical and immunohistochemical profiles X-34 and thioflavin S histofluorescence were prominent in CAA and classic plaques in the [C-11]PiB(-) case; however, the majority of plaques were diffuse with weak X-34 ( Fig. 2a) and thioflavin S fluorescence (not shown). The frequency of amyloid plaques in the [C-11]PiB(?) case was high compared to the [C-11]PiB(-) case, with numerous plaques and tangles but only sparse CAA (Fig. 2b) . Labeling of sequential thin paraffin sections from the [C-11]PiB(-) case with 6-CN-PiB and Ab immunohistochemistry (IHC using the 6E10 antibody, Table 1 ) demonstrated that 6-CN-PiB signal was weak in diffuse Ab-immunoreactive plaques, and prominent in classic Ab plaques and in CAA (Fig. 3) . 6-CN-PiB plaque load was very low (0-0.05% area), whereas Ab immunoreactive plaque load reached 1.8% (Fig. 3e, inset; Fig. 4 ). Ab immunoreactive and 6-CN-PiB histofluorescent plaque load in the [C-11]PiB(-) case correlated weakly (r = 0.47; p \ 0.06).
In the [C-11]PiB(?) case, high densities of 6-CN-PiB labeled plaques were observed in all cortical areas and there was a significant correlation between Ab IHC and 6-CN-PiB histofluorescence (r = 0.89; p \ 0.0001; Fig. 3 ). The percent area occupied with Ab immunoreactive plaques was up to 5-fold higher than that observed in the [C-11]PiB(-) case, and plaque loads determined using 6-CN-PiB histofluorescence were comparable to those detected by Ab IHC (Fig. 4) .
Using an antibody generated against mid portion of Ab (clone 4G8, Table 2 ), we observed focal clusters of diffuse plaques and moderate cerebral vascular deposits in the [C-11]PiB(-) case, and high densities of plaques that were uniformly distributed in the [C-11]PiB(?) case (Fig. 5a, b) , comparable to that seen with the 6E10 antibody. We also used antibodies generated against the C-termini of Ab peptides ending at residues 40 or 42 (Abx-40 and Abx-42, Table 2 ), as well as an antibody directed against the pyroglutamate modification of N-terminally truncated Ab (N3pE, see Table 2 ) [12] , postulated to be a component of recently formed Ab plaques [45] . There were no differences in the overall frequency or the distribution pattern of Ab plaques using antibodies generated against different portions of the Ab peptide. In the [C-11]PiB(-) case, all antibodies revealed sparse to focally dispersed clusters of cortical Ab plaques; classic and burnt out Ab plaques comprised a relatively small portion of the total plaque load, with the bulk of the deposits appearing diffuse (Fig. 5c-g ). This was in sharp contrast to high densities of diffuse and classic Ab plaques labeled with the same antibodies in the [C-11]PiB(?) case (Fig. 5h-l) . (Table 3) .
In the [C-11]PiB(-) case, the frontal pole had the highest Ab1-42 concentration (788 pmol/g) which was up to 50% lower than the Ab1-42 concentration in the same brain region and other cortical regions from the [C-11]PiB(?) case (Table 3 (Fig. 6a, b) .
A conservative positive cutoff for positive [C-11]PiB PET retention was defined as an atrophy-corrected DVR of 1.4 [1] . However, this cutoff value is brain region (Fig. 6a-c) . Table 3 Table 3 ). The two mesial temporal cortex samples (hippocampus and subiculum/entorhinal cortex) fell into the 1.2-1.4 DVR indeterminate range, and only the cerebellum had a [C-11]PiB PET DVR value less than 1.2 ( Fig. 6; Table 3 ). (Fig. 6a, FP) . The frontal pole, like all other areas in the [C-11]PiB(-) case, had a DVR value that was clearly below the DVR = 1.2 cutoff for [C-11]PiB PET positivity ( Fig. 6a; Table 3 ).
Ab1-40 levels in neocortical areas from the [C-11]PiB(?) case ranged from 118 to 459 pmol/g (Table 3) had higher concentration of Ab1-42 (Fig. 6a) . In the [C-11]PiB(-) case, Ab1-40 concentrations in the frontal pole and three other neocortical areas were in the middle of the Ab1-40 value range in the [C-11]PiB(?) case, while all other areas were at low end of Ab1-40 detection ( Fig. 6b ; Table 3 ). (Fig. 6c) . The cerebellum was the only region in the [C-11]PiB(?) case that had a DVR value below 1.2; this region had a [H-3]PiB binding value of 106 pmol/g (Fig. 6c) (Fig. 6c) .
Antemortem [C-11]PiB PET DVR values also were compared to region-matched Ab plaque loads that were determined postmortem in the [C-11]PiB(?) and the [C-11]PiB(-) cases (Fig. 7) . There was a direct correlation between DVR values and 6E10 plaque load in the 
Discussion
This study describes and quantifies postmortem amyloid pathology in a subject, clinically diagnosed with DLB and possible AD, who had a negative [C-11]PiB PET scan 17 months before death, and compares the results to region-matched analyses in a subject with clinically severe AD and a positive [C-11]PiB PET scan 10 months before death.
Cortical Ab plaques were detected in both cases, however plaques in the [C-11]PiB(-) case were infrequent, primarily diffuse in morphology, and were labeled weakly with thioflavin S, X-34 and 6-CN-PiB. Although some cortical regions in the [C-11]PiB(-) case had focal areas of moderate and even high frequencies of Bielschowsky positive neuritic plaques, these lesions are not representative of the entire region's pathology because semiquantitative assessments of plaque frequencies by a standard neuropathological assessment were performed in a 1009 microscopy field placed over the areas of the highest plaque density. [16] . To determine if Ab plaques in the [C-11]PiB(-) case contained proteolytically modified Ab, we performed immunohistochemistry using an array of antibodies targeting the N-terminus (6E10), mid-portion (4G8), and C-terminus (Abx-40 and Abx-42; see Table 2 ) of the Ab [16] . These results were corroborated in the autopsy analysis of the first subject scanned with [C-11]PiB PET [17] .
Cairns and colleagues [6] described the neuropathology of a subject with normal cognition and only background [C-11]PiB retention when PET scanned, but who progressed to very mild clinical AD (CDR = 0.5) a year later. Although Ab deposits were detected histologically at autopsy (30 months after the in vivo [C-11]PiB PET scan), the low frequencies of neuritic plaques were consistent with a diagnosis of only possible AD by CERAD criteria, and there was only a low probability that clinical symptoms were caused by AD pathology according to the NIA/Reagan Institute criteria [6] . In contrast, biochemical analyses in the Cairns [C-11]PiB(-) case showed high levels of postmortem Ab1-42 (up to 1,785 pmol/g) determined by the same ELISA method reported here, well above the highest value we observed in our [C-11]PiB(-) case. Furthermore, the Ab plaque load (up to 5.4% area) in the Cairns [C-11]PiB(-) case also was higher than in the [C-11]PiB(-) case described in our study. Postmortem [6, 41] .
Postmortem pathological correlates of in vivo [C-11]PiB retention were also examined in studies of two [C-11]PiB(-) cases of Creutzfeldt-Jakob disease [49] , three cases of Parkinson's dementia (2 [C-11]PiB(?), 1 [C-11]PiB(-) [5] , a [C-11]PiB(?) case of DLB [19] , and in four [C-11]PiB(-) nondemented cases and in one nondemented and one demented [C-11]PiB(?) case from the Baltimore Longitudinal Study of Aging [46] . In addition to these autopsy studies summarized in Table 1 , Leinonen and colleagues [26] reported a correlation between neuropathology and in vivo [C-11]PiB retention in biopsies from ten cases of suspected normal pressure hydrocephalus (NPH). Correlations were observed in 9/10 cases, but diffuse cortical Ab plaques were found in the frontal biopsy sample from one NPH case with dementia who was subsequently determined to be [C-11]PiB(-) [26] . The small amount of tissue available prevented more detailed histological or biochemical assays in that biopsy study.
Two postmortem PiB-labeling studies without associated in vivo [C-11]PiB PET data also contribute to the characterization of PiB PET as a technique to detect Ab plaque pathology in vivo. Using autoradiography, Lockhart and colleagues [27, 48] reported that [H-3]PiB labels classic and diffuse plaques, CAA, and NFT. PiB labeling of NFT is not supported by other studies and may be due to the low resolution of the autoradiographic technique employed or to the binding of PiB to aggregated Ab associated with extracellular tangles [16] . Rosen et al. [42] studied a series of 10 AD autopsies and largely confirmed previous findings in nine of these cases. One end stage (Braak stage VI) AD case was unusual, with ''copious dense-cored and diffuse'' plaques and ''significant large vessel and capillary CAA'' detected using Ab immunohistochemistry, Congo red, thioflavin T and silver staining [42] . The most unusual feature of this case was extremely high postmortem levels of both Abx-42 ([9,000 pmol/g) and Abx-40 ([26,000 pmol/g), with a predominance of Abx-40, yet extremely low [H-3]PiB binding (\50 pmol/g). In addition, there was an ''unusual distribution of low-and high-molecular weight Ab oligomers, as well as a distinct pattern of N-and C-terminally truncated Ab peptides in both the soluble and insoluble cortical extracts'' [42] . Although no in vivo [C-11] The clinical relevance of Ab pathology in [C-11]PiB(-) cases is unclear. In the Cairns et al. case [6] , the [C-11]PiB(-) subject was cognitively normal (CDR = 0) when the [C-11]PiB PET scan was obtained, suggesting that Ab pathology, if present, was without clinical effect. In the present [C-11]PiB(-) case, the existence of another pathology (Lewy bodies and threads) that can alone contribute to dementia prevents an unambiguous determination of whether the [C-11]PiB(-) Ab deposits contributed to cognitive dysfunction of this patient. Similarly, the Leinonen [C-11]PiB(-) biopsy case had clinically diagnosed NPH [26] . However, in the Rosen case with high insoluble Ab1-40 and low [H-3]PiB binding, only typical AD pathology was noted [42] . Thus, although the in vivo [C-11]PiB PET status of the Rosen case is unknown, this may have been a [C-11]PiB(-) case in which large amounts of an atypical Ab species contributed to the dementia.
In summary, we report histological and biochemical evidence of Ab pathology in a cognitively impaired individual with clinical diagnosis of DLB and no detectable [C-11]PiB retention 17 months before death. These observations, along with the postmortem findings of Cairns et al. [6] and biopsy findings of Leinonen et al. [26] suggest that in vivo [C-11]PiB PET may not be 100% sensitive for the presence of histologically detectable Ab even if the latter were to be determined at the time of the in vivo scan. As a corollary, even weakly-positive [C-11]PiB PET scans will likely be associated with substantial Ab pathology (i.e., high specificity of in vivo [C-11]PiB PET for Ab deposits). However, no accurate determinations of pathology level thresholds necessary to elicit a positive PiB PET signal can be made using single or small numbers of cases. 
